上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2024 , Vol. 44 >Issue 10: 1323 - 1329

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.10.015

综述

FOXM1与肿瘤代谢关系的研究进展

  • 李钰 ,
  • 姜艺凡 ,
  • 童荣亮 ,
  • 陈迪宇 ,
  • 吴健
展开
  • 1.浙江大学医学院附属第一医院肝胆胰外科，杭州 310003
    2.卫生部多器官联合移植研究重点实验室，杭州 310003
李 钰（1998—），男，硕士生；电子信箱：li_yu@zju.edu.cn。
吴 健，电子信箱：drwujian@zju.edu.cn。

收稿日期: 2024-03-14

  录用日期: 2024-06-04

  网络出版日期: 2024-10-28

基金资助

浙江省自然科学基金华东医药企业创新发展联合基金资助项目(LHDMD22H310005)

收起

Research progress in the relationship between FOXM1 and neoplasm metabolism

  • Yu LI ,
  • Yifan JIANG ,
  • Rongliang TONG ,
  • Diyu CHEN ,
  • Jian WU
Expand
  • 1.Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
    2.Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou 310003, China.
WU Jian, E-mail: drwujian@zju.edu.cn.

Received date: 2024-03-14

  Accepted date: 2024-06-04

  Online published: 2024-10-28

Supported by

Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China(LHDMD22H310005)

Fold

摘要

FOXM1（forkhead box M1）是FOX转录因子家族中的重要成员，其已被证实通过转录调控作用影响诸多肿瘤细胞演进。此外，FOXM1高表达与多种癌症不良预后相关，其参与调控基因表达，细胞增殖、侵袭、转移和凋亡等多种生物学过程。肿瘤细胞中的代谢重编程是肿瘤的重要特征，决定了肿瘤细胞的存活、生长和增殖。随着研究的不断深入，越来越多的证据提示FOXM1在调节肿瘤细胞增殖与代谢之间起“桥梁”作用，成为衔接肿瘤细胞生物行为学与代谢的枢纽。该文对FOXM1与肿瘤细胞代谢关系的研究进展进行综述，旨在为研发基于FOXM1的新型靶向药物提供理论参考。

关键词： FOXM1; 肿瘤; 代谢; 抑制剂; 肿瘤微环境

本文引用格式

李钰 , 姜艺凡 , 童荣亮 , 陈迪宇 , 吴健 . FOXM1与肿瘤代谢关系的研究进展[J]. 上海交通大学学报（医学版）, 2024 , 44(10) : 1323 -1329 . DOI: 10.3969/j.issn.1674-8115.2024.10.015

Abstract

FOXM1 (forkhead box M1) is an important member of the FOX transcription factor family and plays a critical role in driving the progression of multiple malignancies through its transcriptional regulatory functions. Moreover, the overexpression of FOXM1 is associated with poor prognosis in many types of cancer, as it regulates a variety of biological processes such as gene expression, cell proliferation, invasion, metastasis, and apoptosis. Presently, aberrant metabolic reprogramming has been considered as the major characteristic of cancer development, determining the survival, growth, and proliferation of tumor cells. Accumulating evidence suggests that FOXM1 serves as a "bridge" between metabolism and tumorigenesis. This review aims to provide a comprehensive summary of the research progress in the relationship between FOXM1 and tumor cell metabolism, offering theoretical insights for the development of novel anti-cancer drugs targeting FOXM1.

Key words： forkhead box M1 (FOXM1); tumor; metabolism; inhibitor; tumor microenvironment

参考文献

1 FAUBERT B, SOLMONSON A, DEBERARDINIS R J. Metabolic reprogramming and cancer progression[J]. Science, 2020, 368(6487): eaaw5473.
2 关永俊, 余佳, 王卫星. 转录因子与肿瘤代谢重编程的研究进展[J]. 腹部外科, 2022, 35(2): 136-140.
2 GUAN Y J, YU J, WANG W X. Research advances of transcription factors and tumor metabolic reprogramming[J]. Journal of Abdominal Surgery, 2022, 35(2): 136-140.
3 BACH D H, LONG N P, LUU T T, et al. The dominant role of forkhead box proteins in cancer[J]. Int J Mol Sci, 2018, 19(10): E3279.
4 LIAO G B, LI X Z, ZENG S, et al. Regulation of the master regulator FOXM1 in cancer[J]. Cell Commun Signal, 2018, 16(1): 57.
5 ABDELJAOUED S, BETTAIEB I, NASRI M, et al. Overexpression of FOXM1 is a potential prognostic marker in male breast cancer[J]. Oncol Res Treat, 2017, 40(4): 167-172.
6 EGAWA M, YOSHIDA Y, OGURA S, et al. Increased expression of Forkhead box M1 transcription factor is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma[J]. Hepatol Res, 2017, 47(11): 1196-1205.
7 ITO T, KOHASHI K, YAMADA Y, et al. Prognostic significance of forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in angiosarcoma[J]. J Cancer, 2016, 7(7): 823-830.
8 KONG F F, QU Z Q, YUAN H H, et al. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer[J]. Oncol Rep, 2014, 31(6): 2660-2668.
9 TASSI R A, TODESCHINI P, SIEGEL E R, et al. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients[J]. J Exp Clin Cancer Res, 2017, 36(1): 63.
10 ZHANG H, ZHONG H, LI L, et al. Overexpressed transcription factor FOXM1 contributes to the progression of colorectal cancer[J]. Mol Med Rep, 2016, 13(3): 2696-2700.
11 GARBER K. Energy deregulation: licensing tumors to grow[J]. Science, 2006, 312(5777): 1158-1159.
12 CHEN J Q, RUSSO J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells[J]. Biochim Biophys Acta, 2012, 1826(2): 370-384.
13 CUI J, SHI M, XIE D, et al. FOXM1 promotes the Warburg effect and pancreatic cancer progression via transactivation of LDHA expression[J]. Clin Cancer Res, 2014, 20(10): 2595-2606.
14 JIANG W, ZHOU F, LI N, et al. FOXM1-LDHA signaling promoted gastric cancer glycolytic phenotype and progression[J]. Int J Clin Exp Pathol, 2015, 8(6): 6756-6763.
15 SHANG R, PU M, LI Y, et al. FOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expression[J]. Oncol Rep, 2017, 37(4): 2261-2269.
16 WANG Y, YUN Y, WU B, et al. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription[J]. Oncotarget, 2016, 7(30): 47985-47997.
17 KUAI X Y, LEI Z Y, LIU X S, et al. The interaction of GLUT1 and FOXM1 leads to a poor prognosis in colorectal cancer[J]. Anticancer Agents Med Chem, 2020, 20(8): 941-950.
18 WANG K, DAI X, YU A, et al. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression[J]. J Exp Clin Cancer Res, 2022, 41(1): 289.
19 ZHANG W, ZHANG X, HUANG S, et al. FOXM1D potentiates PKM2-mediated tumor glycolysis and angiogenesis[J]. Mol Oncol, 2021, 15(5): 1466-1485.
20 JIANG Z P, HU H, HU W L, et al. Circ-RNF121 regulates tumor progression and glucose metabolism by miR-1224-5p/FOXM1 axis in colorectal cancer[J]. Cancer Cell Int, 2021, 21(1): 596.
21 CHENG Y, SUN F M, THORNTON K, et al. FOXM1 regulates glycolysis and energy production in multiple myeloma[J]. Oncogene, 2022, 41: 3899-3911.
22 HAO Y, LI D, XU Y, et al. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data[J]. BMC Bioinformatics, 2019, 20(suppl 7): 195.
23 EZZEDDINI R, TAGHIKHANI M, SOMI M H, et al. Clinical importance of FASN in relation to HIF-1α and SREBP-1c in gastric adenocarcinoma[J]. Life Sci, 2019, 224: 169-176.
24 JIA J, CHE L, CIGLIANO A, et al. Pivotal role of fatty acid synthase in c-MYC driven hepatocarcinogenesis[J]. Int J Mol Sci, 2020, 21(22): E8467.
25 ASSAILY W, RUBINGER D A, WHEATON K, et al. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress[J]. Mol Cell, 2011, 44(3): 491-501.
26 FAJAS L, LANDSBERG R L, HUSS-GARCIA Y, et al. E2Fs regulate adipocyte differentiation[J]. Dev Cell, 2002, 3(1): 39-49.
27 DE OLANO N, KOO C Y, MONTEIRO L J, et al. The p38 MAPK-MK2 axis regulates E2F1 and FOXM1 expression after epirubicin treatment[J]. Mol Cancer Res, 2012, 10(9): 1189-1202.
28 GUAITA-ESTERUELAS S, BOSQUET A, SAAVEDRA P, et al. Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins[J]. Mol Carcinog, 2017, 56(1): 208-217.
29 ZHANG X, HUANG C, YUAN Y, et al. FOXM1-mediated activation of phospholipase D1 promotes lipid droplet accumulation and reduces ROS to support paclitaxel resistance in metastatic cancer cells[J]. Free Radic Biol Med, 2022, 179: 213-228.
30 CALDWELL S A, JACKSON S R, SHAHRIARI K S, et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1[J]. Oncogene, 2010, 29(19): 2831-2842.
31 LYNCH T P, FERRER C M, JACKSON S R, et al. Critical role of O-Linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis [J]. J Biol Chem, 2012, 287(14): 11070-11081.
32 FERRER C M, LU T Y, BACIGALUPA Z A, et al. O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway[J]. Oncogene, 2017, 36(4): 559-569.
33 PARK H J, CARR J R, WANG Z, et al. FoxM1, a critical regulator of oxidative stress during oncogenesis[J]. EMBO J, 2009, 28(19): 2908-2918.
34 HALASI M, PANDIT B, WANG M, et al. Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth[J]. Am J Pathol, 2013, 183(1): 257-265.
35 NEWICK K, CUNNIFF B, PRESTON K, et al. Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells[J]. PLoS One, 2012, 7(6): e39404.
36 XIA L M, HUANG W J, WANG B, et al. Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1[J]. J Cell Biochem, 2009, 106(2): 247-256.
37 WEI W S, WANG N, DENG M H, et al. LRPPRC regulates redox homeostasis via the circANKHD1/FOXM1 axis to enhance bladder urothelial carcinoma tumorigenesis[J]. Redox Biol, 2021, 48: 102201.
38 YUNG M M, CHAN D W, LIU V W, et al. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade[J]. BMC Cancer, 2013, 13: 327.
39 HU C, LIU D, ZHANG Y, et al. LXRα-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells[J]. Oncogene, 2014, 33(22): 2888-2897.
40 ECKERS J C, KALEN A L, SARSOUR E H, et al. Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells[J]. Radiat Res, 2014, 182(4): 420-429.
41 PETROVIC V, COSTA R H, LAU L F, et al. Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin[J]. Cancer Biol Ther, 2010, 9(12): 1008-1016.
42 DONG G Z, JEONG J H, LEE Y I, et al. Diarylheptanoids suppress proliferation of pancreatic cancer PANC-1 cells through modulating shh-Gli-FoxM1 pathway[J]. Arch Pharmacal Res, 2017, 40(4): 509-517.
43 HALASI M, HITCHINSON B, SHAH B N, et al. Honokiol is a FOXM1 antagonist[J]. Cell Death Dis, 2018, 9: 84.
44 JIANG L, CAO X C, CAO J G, et al. Casticin induces ovarian cancer cell apoptosis by repressing FoxM1 through the activation of FOXO3a[J]. Oncol Lett, 2013, 5(5): 1605-1610.
45 BI Z, LIU W, DING R, et al. A novel peptide, 9R-P201, strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down-regulation of FoxM1 expression[J]. Eur J Pharmacol, 2017, 796: 175-189.
46 XIANG Q, TAN G X, JIANG X, et al. Suppression of FOXM1 transcriptional activities via a single-stranded DNA aptamer generated by SELEX[J]. Sci Rep, 2017, 7: 45377.
47 PANDIT B, GARTEL A L. FoxM1 knockdown sensitizes human cancer cells to proteasome inhibitor-induced apoptosis but not to autophagy[J]. Cell Cycle, 2011, 10(19): 3269-3273.
48 HEGDE N S, SANDERS D A, RODRIGUEZ R, et al. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton[J]. Nat Chem, 2011, 3: 725-731.
49 GARTEL A L. Thiazole antibiotics siomycin a and thiostrepton inhibit the transcriptional activity of FOXM1[J]. Front Oncol, 2013, 3: 150.
50 GORMALLY M V, DEXHEIMER T S, MARSICO G, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition[J]. Nat Commun, 2014, 5: 5165.
51 SHUKLA S, MILEWSKI D, PRADHAN A, et al. The FOXM1 inhibitor RCM-1 decreases carcinogenesis and nuclear β-catenin[J]. Mol Cancer Ther, 2019, 18(7): 1217-1229.
52 ZIEGLER Y, LAWS M J, SANABRIA GUILLEN V, et al. Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds[J]. NPJ Breast Cancer, 2019, 5: 45.
53 TEH M T. FOXM1 wins molecule of the year 2010 [EB/OL]. [2011-02-20]. http://ismcbbpr.synthasite.com/molyearnews/foxm1-wins-molecule-of-the-year-2010.
Options
文章导航

/

〈 〉